Lipogen Products Ltd.

Lipogen is a science-driven manufacturer and developer of patented phospholipid compounds and multi-action formulas specifically targeted at cognitive health and brain function. Founded in 1991 in partnership with Professor Meir Shinitzky and Dr. Avner Sheinfeld from the Weizmann Institute of Science, the company has spent over three decades pioneering research and commercial development of phospholipid-based dietary supplements. Operating globally, Lipogen supplies its proprietary ingredients and finished formulas to markets across numerous countries worldwide.

The company's core product portfolio centers on three key phospholipids: phosphatidylserine (PS), phosphatidic acid (PA), and phosphatidylcholine (PC). These are offered under branded product lines including Aqua PS™, Aqua PA™, and CognoLipid™. Phospholipids are critical structural components of cell membranes, and Lipogen's formulas are clinically designed to support membrane integrity, brain performance, memory, stress reduction, and women's health — including premenstrual syndrome (PMS) management.

A major differentiator for Lipogen is its proprietary, patented manufacturing process — a water-based, solvent-free production method that distinguishes the company from conventional supplement manufacturers. This process yields shelf-stable, environmentally responsible products while maintaining rigorous quality and safety standards. The company holds multiple product patents and has established a benchmark for safety and efficacy in the nutraceutical and dietary supplement industries.

Lipogen's scientific credibility is underscored by an extensive body of clinical evidence. Its clinical studies have been published in major peer-reviewed scientific and medical journals, covering areas such as memory performance in healthy individuals, cognitive function in Alzheimer's disease patients, cortisol stress hormone regulation, and women's hormonal health. The company was the first to clinically test soy-lecithin-derived phosphatidylserine and to introduce PS globally as a commercially viable ingredient.

On the regulatory front, Lipogen has achieved several significant milestones. In 2003, the U.S. Food and Drug Administration (FDA) granted phosphatidylserine a Qualified Health Claim, allowing label language stating that PS 'may reduce the risk of dementia or cognitive dysfunction in the elderly' — a distinction that, as of 2019, PS held uniquely among nutritional supplements. In 2006, Lipogen formulas received FDA GRAS (Generally Recognized As Safe) designation. In 2016, the company earned the European Union's Novel Food safety certification, one of the most rigorous regulatory approvals in the European nutraceutical market.

Lipogen also collaborated with Lonza, a major Swiss pharmaceutical company, beginning in 2010, reflecting the company's standing as a credible, high-quality ingredient supplier in the global life sciences and nutraceutical supply chain. The company supports its B2B partners through marketing programs, product branding options, and co-branding support, making it a viable private-label or ingredient supply partner for supplement brands and CPG manufacturers seeking clinically validated, regulatory-compliant cognitive health ingredients.

The Nombase Funding database has 4,288 records from over 1,788 companies.

There's no funding data for this company.